Rapport Therapeutics, Inc.

RAPP

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0002012593

SEC filings (opens in a new tab)

In the last 90 days, Rapport Therapeutics, Inc. insiders filed 7 open-market purchases and 8 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 9, 2026: $1.55B
Insider buysLast 90 days, $22.0M in total: 7
Insider sellsLast 90 days, $4.49M in total: 8
13F holdersQ2 2026, +16 vs. previous quarter: 160
13F valueReported value at the end of Q2 2026: $2.13B
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: –; No comparable prior period
Net income, FY2025: -$111.5M; No comparable prior period
Free cash flow, FY2025: -$88.1M; No comparable prior period
Revenue, Q3 FY2026: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 15, 2026.

Short interest: 3.05M; Shares sold short
Change: −142.5K; −4.5% vs. previous
Days to cover: 11.76; At average daily volume

Superinvestors holding RAPP, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding RAPP at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Rapport Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 30, 2026 (view filing)7:32 PM ET	Oct 28	2 days	Healy JamesDirector	PPurchase	+969.5K	$21.00	+$20.4M	New position25.3K after	4 lots
Oct 23, 2026 (view filing)4:30 PM ET	Oct 21	2 days	Ceesay AbrahamChief Executive Officer	SSale	−2.21K	$29.16	−$64.4K	−0.5%450.0K after	10b5-1
Oct 23, 2026 (view filing)4:01 PM ET	Oct 23	Same day	Sanchez RamiroDirector	PPurchase	+3.60K	$27.35	+$98.5K	New position3.60K after
Oct 22, 2026 (view filing)4:57 PM ET	Oct 22	Same day	Silva Paul MDirector	PPurchase	+3.68K	$27.08	+$99.6K	New position3.68K after
Oct 22, 2026 (view filing)4:56 PM ET	Oct 22	Same day	Young Wendy B.Director	PPurchase	+3.79K	$26.39	+$100.0K	+39.9%13.3K after
Oct 22, 2026 (view filing)4:56 PM ET	Oct 22	Same day	Paul Steven MDirector	PPurchase	+35.7K	$27.28	+$974.3K	+85.7%77.4K after
Oct 22, 2026 (view filing)4:56 PM ET	Oct 22	Same day	Maraganore JohnDirector	PPurchase	+9.41K	$26.45	+$248.9K	New position9.41K after	2 lots
Oct 21, 2026 (view filing)5:46 PM ET	Oct 21	Same day	Ignelzi Troy A.Chief Financial Officer	PPurchase	+5.50K	$26.10	+$143.6K	+55.0%15.5K after
Oct 8, 2026 (view filing)4:07 PM ET	Oct 6-7	2 days	Ceesay AbrahamChief Executive Officer	SSale	−4.52K	$31.68	−$143.3K	−1.0%452.2K after	2 lots10b5-1
Oct 1, 2026 (view filing)4:30 PM ET	Sep 30	1 day	Gault CherylChief Operating Officer	SSale	−10.0K	$33.19	−$331.9K	−6.7%139.9K after	2 lots10b5-1

Top 10 13F holders, Q2 2026

See all 160 holders

The largest institutional positions in Rapport Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding RAPP in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
FMR LLC	7,172,894	$298.9M	0.01%	+3,955+0.1%	Added
TRV GP V, LLC	6,280,525	$261.7M	52.53%	−854,708−12.0%	Reduced
ARCH Venture Management, LLC	3,728,738	$155.4M	14.12%	00.0%	Unchanged
Capital International Investors	2,921,958	$121.8M	0.03%	−176,015−5.7%	Reduced
Goldman Sachs Group Inc	2,910,449	$121.3M	0.01%	−31,802−1.1%	Reduced
BlackRock, Inc.	2,699,786	$112.5M	0.00%	+193,831+7.7%	Added
Cormorant Asset Management, LP	2,657,521	$110.7M	5.67%	−300,000−10.1%	Reduced
Sofinnova Investments, Inc.	1,904,408	$79.4M	4.24%	00.0%	Unchanged
Johnson & Johnson	1,784,517	$74.4M	9.31%	00.0%	Unchanged
Polar Capital Holdings Plc	1,608,514	$67.0M	0.19%	−33,947−2.1%	Reduced

Holders of 5% or more of RAPP

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Rapport Therapeutics, Inc..

Largest holders of RAPP from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Third Rock Ventures V, L.P.	13G/A	13.10%6.28M shares	−6.40 ppfrom 19.50%	Feb 13, 20252 filings	Aug 14, 2026	SEC
Capital International Investors	13G/A	6.10%2.92M shares	–	Nov 13, 20242 filings	Aug 12, 2026	SEC
Cormorant Asset Management, LP	13G/A	5.56%2.66M shares	−0.63 ppfrom 6.19%	Jun 20, 20246 filings	Aug 14, 2026	SEC
BlackRock, Inc.	13G	5.03%2.40M shares	New	Jan 21, 20261 filing	Jan 21, 2026	SEC